



# IMI AMR Accelerator

## About the AMR Accelerator

The Innovative Medicines Initiative (IMI), funded by the European Union and the European pharmaceutical industry, responded to the challenge of AMR and launched the AMR Accelerator in 2019. With a total budget of 295M €, 57 partners from large pharmaceutical companies, small and medium-sized enterprises, not-for-profit organisations and the public sector in seven consortia are working to advance a broad, unparalleled portfolio of programmes that target Gram-negative bacteria, *Mycobacterium tuberculosis* and non-tuberculous mycobacteria (NTM).

The AMR Accelerator as a whole has the ambitious goal to deliver up to 10 new preclinical candidates and up to 5 Phase II-ready assets by 2025.

### The AMR Accelerator Portfolio

57

Participants

295

M€ Budget

7

Projects

13

Programmes in the Portfolio

Last update 02/2021

AMR Accelerator Project	Asset Owner	Programme	Novelty		Development Stage				
			New Class	New MoA	Discovery	(Pre)-Hit to Lead	Lead to Candidate	Candidate to Phase I	Phase I
BNA NOW	EVOTEC	Corramycin	✓	✓			▶		
	NOSOPHARM	NOSO-502	✓	✓				▶	
		NOSO-2G	✓	✓			▶		
TRIC-TB	BioVersys and GSK	Boasting Ethionamide	✓	✓					▶
AB-Direct	GSK	Gepotidacin tissue distribution	✓	✓				▶	
ERA4TB	GSK	ERA4TB GSK1	✓	✓					▶
		ERA4TB GSK2	✓	✓			▶		
	TBA	ERA4TB TBA1							▶
		ERA4TB TBA2					▶		
	DDU	ERA4TB DDU1					▶		
RespiriTB & NTM	JANSSEN	JUNJ901							▶
		RespiriTB	✓	✓	▶				
		RespiriNTM				▶			
Accelerating scientific discoveries in the AMR field									
COMBINE		Providing learnings derived from shared vaccine and/or antibacterial clinical trial data and improving understanding of variability and translatability of animal models of bacterial infection.							

# About COMBINE

At the core of the Accelerator is the COMBINE project, a 'Capability Building Network', which coordinates cross-project tasks, but also has its own scientific aims (e.g. to optimise the design of clinical trials and improve animal models used in AMR research) in order to support all Accelerator projects in achieving their goals.

Part of COMBINE's efforts are to promote awareness of the Accelerator projects' activities and results, support outreach activities and establish contacts with other initiatives in the field via targeted networking.

A Networking Strategy is currently being developed to strengthen the interaction with key stakeholders and promote communication and collaboration across the global AMR landscape.

## Disclaimer

This factsheet reflects the authors' view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.

[www.imi.europa.eu](http://www.imi.europa.eu)

[www.amr-accelerator.eu](http://www.amr-accelerator.eu)

Projects in the AMR Accelerator:




AMR ACCELERATOR PARTNERS:

ASCLEPIA OUTSOURCING SOLUTIONS | BEAM ALLIANCE | BILL & MELINDA GATES FOUNDATION | BIOASTER | BIOCOM | BIOVERSYS | C-PATH | CHU DE POITIERS | CONSIGLIO NAZIONALE DELLE RICERCHE | ÉCOLE POLYTECHNIQUE FEDERALE DE LAUSANNE | ERASMUS MC UNIVERSITY | EVOTEC | FFUND | FORSCHUNGSZENTRUM BORSTEL | FOUNDATION INNOVATIVE MEDICINES FOR TUBERCULOSIS | FRAUNHOFER GESELLSCHAFT | GRITSYSTEMS AS | GSK | HELMHOLTZ CENTRE FOR INFECTION RESEARCH | HIPS | HOPITEAUX DE TOURS | IDMIT | IMABIOTECH | INSERM | INSTITUTE PASTEUR PARIS | INSTITUTE PASTEUR DE LILLE FOUNDATION | JANSSEN | LATVIA INSTITUTE OF ORGANIC SYNTHESIS | LEIDS UNIVERSITAIR MEDISCH CENTRUM | LYGATURE | MEDICAL UNIVERSITY OF VIENNA | MITOLOGICS | NHS | NICE | NOSOPHARM | PAUL-EHRlich-INSTITUT | PUBLIC HEALTH ENGLAND | QPS NETHERLANDS | SCIENSANO | SERMAS | SKANE HOSPITAL LUND | STATENS SERUM INSTITUT | SYNAPSE RESEARCH MANAGEMENT PARTNERS | TB ALLIANCE | UNIVERSITE DE POITIERS | UNIVERSITE PARIS SORBONNE | UNIVERSITEIT LEIDEN | UNIVERSITET ANTWERPEN | UNIVERSIDAD CARLOS III MADRID | UNIVERSITY OF COPENHAGEN | UNIVERSITY OF DUNDEE | UNIVERSITY OF KÖLN | UNIVERSITY OF LIVERPOOL | UNIVERSITY OF PADOVA | UNIVERSITY OF PAVIA | UNIVERSITY OF ZARAGOZA | UPPSALA UNIVERSITET



IMI Associated Partners for ERA4TB



The AMR Accelerator receives funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853976 | 853967 | 853979 | 853932 | 853903 | 853800 | 853989. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. ERA4TB receives additional support from Global Alliance for TB Drug Development, Bill & Melinda Gates Foundation and University of Dundee.